Review Volume 10, Issue 12 pp 4248—4268

How I treat elderly patients with plasma cell dyscrasias

Figure 2. Recommendations for the treatment of previously treated patients with Waldenstrom’s Macroglobulinemia. Figure adjusted from ESMO guidelines for WM 2018 and EMN recommendations for treatment of rare plasma cell dyscrasias. R: rituximab.